Antiretroviral therapy intensification for HIV-associated neurocognitive disorder?

Affiliations

¹ Departments of Neurology and HIV Medicine and Peter Duncan Neurosciences Unit St Vincent's Hospital, University of New South Wales and Notre Dame, Sydney, New South Wales, Australia.
² Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA.

Comment

Bruce J Brew et al. AIDS. 2023.

. 2023 Nov 1;37(13):2095-2096.

doi: 10.1097/QAD.0000000000003694. Epub 2023 Sep 28.

¹ Departments of Neurology and HIV Medicine and Peter Duncan Neurosciences Unit St Vincent's Hospital, University of New South Wales and Notre Dame, Sydney, New South Wales, Australia.
² Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA.

No abstract available

Comment on

Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment.
Shikuma CM, Wojna V, De Gruttola V, Siriwardhana C, Souza SA, Rodriguez-Benitez RJ, Turner EH, Kallianpur K, Bolzenius J, Chow D, Matos M, Shiramizu B, Clements DM, Premeaux TA, Ndhlovu LC, Paul R. Shikuma CM, et al. AIDS. 2023 Nov 1;37(13):1987-1995. doi: 10.1097/QAD.0000000000003650. Epub 2023 Jul 6. AIDS. 2023. PMID: 37418541 Free PMC article. Clinical Trial.

1. Shikuma CM, Wojna V, De Gruttola V, Siriwardhana C, Souza SA, Rodriguez-Benitez RJ, et al. Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment . AIDS 2023; 37:1987–1995.
1. Cochrane CR, Angelovich TA, Byrnes SJ, Waring E, Guanizo AC, Trollope GS, et al. Intact HIV proviruses persist in the brain despite viral suppression with ART . Ann Neurol 2022; 92:532–544.
1. Woodburn BM, Kanchi K, Zhou S, Colaianni N, Joseph SB, Swanstrom R. Characterization of macrophage-tropic HIV-1 infection of central nervous system cells and the influence of inflammation . J Virol 2022; 96:e0095722.
1. Aung HL, Siefried KJ, Gates TM, Brew BJ, Mao L, Carr A, Cysique LA. Meaningful cognitive decline is uncommon in virally suppressed HIV, but sustained impairment, subtle decline and abnormal cognitive aging are not . EClinicalMedicine 2022; 56:101792.
1. Heaton RK, Ellis RJ, Tang B, Marra CM, Rubin LH, Clifford DB, et al. Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study . Brain 2023; 146:1121–1131.